FDA Clears Eloxx's Exaluren for Phase 2 Trial in ADPKD

Bitget2026/10/29 12:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA cleared Eloxx Pharmaceuticals' exaluren IND for nonsense-mutation autosomal dominant polycystic kidney disease, enabling U.S. participation in the EXPRESS Phase 2 trial.
The trial targets approximately 60 patients receiving exaluren or placebo for 52 weeks; first dosing is expected in the third quarter of 2027.
Topline results are expected in the first half of 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eloxx Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610290800PR_NEWS_USPR_____NE84314) on October 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

FDA Clears Eloxx's Exaluren for Phase 2 Trial in ADPKD

You may also like

Crypto prices